Ernesto R.
- Country
- Italy
- Department
- Oncology
Research Overview
- Phase 1/2a Study of REGN10597 Alone or with Cemiplimab in Patients with Advanced Solid Tumours, Melanoma, or Clear-Cell Renal Cell Carcinoma
- Neoadjuvant Evaluation of Darovasertib in Patients with Localized Uveal Melanoma
- A Phase 2 Peri-operative Trial of Fianlimab and Cemiplimab Compared with Anti-PD1 Alone in Patients with Resectable Stage III and IV Melanoma
Data & Insights
Has run more than one trial at 81 of 178 partner sites.
Specializations
Melanoma Specialization
This investigator demonstrates particular expertise in treating various forms of melanoma, with a specific focus on uveal melanoma and advanced melanoma conditions.
- Previously treated non-ocular advanced melanoma
- Metastatic uveal melanoma
- Primary uveal melanoma
The investigator works with novel therapeutic approaches for both early-stage and advanced cases.
Therapeutic Approaches
The investigator specializes in various treatment modalities including neoadjuvant therapy and combination therapy approaches.
- First-line therapy development
- Monotherapy applications
- Pre-surgical tumor management
Their work encompasses both targeted treatments and immunotherapy applications.
Treatment Innovation
The investigator works with emerging therapeutic agents including darovasertib and tebentafusp for melanoma treatment.
- Novel drug combinations
- Targeted therapy optimization
- Treatment response evaluation
Their research includes assessment of tumor response and survival outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.